Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women.

Breast cancer research and treatment

Volumn 140, Issue 3, 2013, Pages 567-575

  Botteri, Edoardo ^a   Munzone, Elisabetta ^b   Rotmensz, Nicole ^b   Cipolla, Carlo ^b   De Giorgi, Vincenzo ^b   Santillo, Barbara ^b   Zanelotti, Arnaldo ^b   Adamoli, Laura ^b   Colleoni, Marco ^b   Viale, Giuseppe ^b   Goldhirsch, Aron ^b   Gandini, Sara ^b  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84898702870     PISSN: None     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2654-3     Document Type: Article

References (24)

1. 1. CV Ram 2010 Beta-blockers in hypertension Am J Cardiol 106 12 1819 1825 21126627 10.1016/j.amjcard.2010.08.023 1:CAS:528:DC%2BC3cXhsFWqtbjJ Ram CV (2010) Beta-blockers in hypertension. Am J Cardiol 106(12):1819–1825
2. 2. HH Grytli MW Fagerland SD Fosså 2013 Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease Eur Urol 64 1 e11 e12 23602404 10.1016/j.eururo.2013.03.045 Grytli HH, Fagerland MW, Fosså SD et al (2013) Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 64(1):e11–e12
3. 3. HH Grytli MW Fagerland SD Fosså 2013 Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy Prostate 73 3 250 260 22821802 10.1002/pros.22564 1:CAS:528:DC%2BC3sXhsVais78%3D Grytli HH, Fagerland MW, Fosså SD et al (2013) Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate 73(3):250–260
4. 4. A Melhem-Bertrandt M Chavez-Macgregor X Lei 2011 Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer J Clin Oncol 29 19 2645 2652 21632501 10.1200/JCO.2010.33.4441 1:CAS:528:DC%2BC3MXpvFWltbo%3D Melhem-Bertrandt A, Chavez-Macgregor M, Lei X et al (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29(19):2645–2652
5. 5. TI Barron RM Connolly L Sharp 2011 Beta blockers and breast cancer mortality: a population-based study J Clin Oncol 29 19 2635 2644 21632503 10.1200/JCO.2010.33.5422 1:CAS:528:DC%2BC3MXpvFWltb0%3D Barron TI, Connolly RM, Sharp L et al (2011) Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 29(19):2635–2644
6. 6. DG Powe MJ Voss KS Zänker 2010 Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival Oncotarget 1 7 628 638 21317458 Powe DG, Voss MJ, Zänker KS et al (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 1(7):628–638
7. 7. PA Ganz LA Habel EK Weltzien 2011 Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort Breast Cancer Res Treat 129 2 549 556 21479924 10.1007/s10549-011-1505-3 1:CAS:528:DC%2BC3MXpvFyiurk%3D Ganz PA, Habel LA, Weltzien EK et al (2011) Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort. Breast Cancer Res Treat 129(2):549–556
8. 8. HM Wang ZX Liao R Komaki 2013 Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy Ann Oncol 24 5 1312 1319 23300016 10.1093/annonc/mds616 1:STN:280:DC%2BC3s3nvVahtw%3D%3D Wang HM, Liao ZX, Komaki R et al (2013) Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 24(5):1312–1319
9. 9. ES Diaz BY Karlan AJ Li 2012 Impact of beta blockers on epithelial ovarian cancer survival Gynecol Oncol 127 2 375 378 22819786 10.1016/j.ygyno.2012.07.102 1:CAS:528:DC%2BC38XhtFKit7rO Diaz ES, Karlan BY, Li AJ (2012) Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 127(2):375–378
10. 10. V Giorgi De M Grazzini S Gandini 2011 Treatment with β-blockers and reduced disease progression in patients with thick melanoma Arch Intern Med 171 8 779 781 21518948 10.1001/archinternmed.2011.131 De Giorgi V, Grazzini M, Gandini S et al (2011) Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 171(8):779–781
11. 11. S Lemeshow HT Sørensen G Phillips 2011 β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study Cancer Epidemiol Biomarkers Prev 20 10 2273 2279 21933972 10.1158/1055-9965.EPI-11-0249 1:CAS:528:DC%2BC3MXht1Oms73F Lemeshow S, Sørensen HT, Phillips G et al (2011) β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study. Cancer Epidemiol Biomarkers Prev 20(10):2273–2279
12. 12. M Monami L Filippi A Ungar 2013 Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials Curr Med Res Opin 29 4 369 378 23368896 10.1185/03007995.2013.772505 1:CAS:528:DC%2BC3sXktFOgtbk%3D Monami M, Filippi L, Ungar A et al (2013) Further data on beta-blockers and cancer risk: observational study and meta-analysis of randomized clinical trials. Curr Med Res Opin 29(4):369–378
13. 13. L Perron I Bairati F Harel 2004 Antihypertensive drug use and the risk of prostate cancer (Canada) Cancer Causes Control 15 6 535 541 15280632 10.1023/B:CACO.0000036152.58271.5e Perron L, Bairati I, Harel F et al (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15(6):535–541
14. 14. DG Powe F Entschladen 2011 Targeted therapies: using β-blockers to inhibit breast cancer progression Nat Rev Clin Oncol 8 9 511 512 21808268 10.1038/nrclinonc.2011.123 Powe DG, Entschladen F (2011) Targeted therapies: using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 8(9):511–512
15. 15. MH Antoni SK Lutgendorf SW Cole 2006 The influence of bio-behavioural factors on tumour biology: pathways and mechanisms Nat Rev Cancer 6 3 240 248 16498446 10.1038/nrc1820 1:CAS:528:DC%2BD28Xhslelt7w%3D Antoni MH, Lutgendorf SK, Cole SW et al (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6(3):240–248
16. 16. SW Cole AK Sood 2012 Molecular pathways: beta-adrenergic signaling in cancer Clin Cancer Res 18 5 1201 1206 22186256 10.1158/1078-0432.CCR-11-0641 1:CAS:528:DC%2BC38Xjt1Wlsbc%3D Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18(5):1201–1206
17. 17. HM Schuller 2010 Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1 7 466 469 21317444 Schuller HM (2010) Beta-adrenergic signaling, a novel target for cancer therapy? Oncotarget 1(7):466–469
18. 18. JP Campbell MR Karolak Y Ma 2012 Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice PLoS Biol 10 7 e1001363 22815651 10.1371/journal.pbio.1001363 1:CAS:528:DC%2BC38XhtVyrs7zN Campbell JP, Karolak MR, Ma Y et al (2012) Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS Biol 10(7):e1001363
19. 19. M Benish I Bartal Y Goldfarb 2008 Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis Ann Surg Oncol 15 7 2042 2052 18398660 10.1245/s10434-008-9890-5 Benish M, Bartal I, Goldfarb Y et al (2008) Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 15(7):2042–2052
20. 20. TL Drell 4th J Joseph K Lang 2003 Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells Breast Cancer Res Treat 80 1 63 70 12889599 10.1023/A:1024491219366 1:CAS:528:DC%2BD3sXkvVCksbw%3D Drell TL 4th, Joseph J, Lang K et al (2003) Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 80(1):63–70
21. 21. EK Sloan SJ Priceman BF Cox 2010 The sympathetic nervous system induces a metastatic switch in primary breast cancer Cancer Res 70 18 7042 7052 20823155 10.1158/0008-5472.CAN-10-0522 1:CAS:528:DC%2BC3cXhtFGqtrrN Sloan EK, Priceman SJ, Cox BF et al (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70(18):7042–7052
22. 22. CJ Daly JC McGrath 2011 Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action Trends Pharmacol Sci 32 219 226 21429599 10.1016/j.tips.2011.02.008 1:CAS:528:DC%2BC3MXksFGruro%3D Daly CJ, McGrath JC (2011) Previously unsuspected widespread cellular and tissue distribution of β-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci 32:219–226
23. 23. L Jansen J Below J Chang-Claude 2012 Beta blocker use and colorectal cancer risk: population-based case–control study Cancer 118 16 3911 3919 22585669 10.1002/cncr.26727 1:CAS:528:DC%2BC38XhtFaksr7J Jansen L, Below J, Chang-Claude J et al (2012) Beta blocker use and colorectal cancer risk: population-based case–control study. Cancer 118(16):3911–3919
24. 24. GV Sørensen PA Ganz SW Cole 2013 Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study J Clin Oncol 31 18 2265 2272 23650417 10.1200/JCO.2012.43.9190 Sørensen GV, Ganz PA, Cole SW et al (2013) Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study. J Clin Oncol 31(18):2265–2272